DUBLIN, June 29, 2020 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced that it will begin
accepting applications for its annual Alkermes Pathways Research
Awards® program on July 1,
2020. This competitive grant program is designed to support
the next generation of researchers working on the front lines to
advance understanding and awareness of disease states in the field
of neuroscience. In its third year, the program will offer grants
to early-career investigators who have demonstrated their
commitment to helping people living with substance use disorders
(SUDs), schizophrenia, and/or bipolar disorder. The application
period will open July 1, 2020 and
will run through October 30,
2020.
"With millions of people in the U.S. impacted by serious mental
illness or substance use disorders, the need for advancements
remains critical," said Craig
Hopkinson, M.D., Executive Vice President, Research &
Development and Chief Medical Officer at Alkermes. "At Alkermes, we
envision a world where diverse communities come together, and
through cutting-edge science, innovative medicine, and strident
advocacy, help address critical public health challenges and pave
the way for meaningful change for people living with serious
chronic diseases. The Pathways program is designed to contribute to
this important effort by supporting a variety of projects across
the U.S. that are focused on advancing research in the field of
neuroscience."
The 3rd annual Alkermes Research Pathways Awards
program offers individual grant amounts of up to $100,000 per project. To qualify, early-career
investigators must be M.D.s, Ph.D.s, or equivalent, who are within
five years of their initial academic appointment or are current
post-doctoral fellows, and who are affiliated with a medical or
research institution within the U.S. Applicants will be evaluated
by an independent review committee comprised of specialists in
psychiatry, neurobiology, pharmacology, and behavioral science from
academic research centers.
The Pathways program began in 2018 and has since provided
funding to researchers across the U.S. Award recipients have
undertaken important, mentor-supported research to help progress
the study of neuroscience. For more information on the Alkermes
Research Pathways Awards program, including the 3rd
annual edition of the program and full eligibility criteria,
visit www.PathwaysResearchAwards.com.
About Alkermes plc
Alkermes plc is a fully
integrated, global biopharmaceutical company developing innovative
medicines in the fields of neuroscience and oncology. The company
has a portfolio of proprietary commercial products focused on
addiction and schizophrenia, and a pipeline of product candidates
in development for schizophrenia, bipolar I disorder,
neurodegenerative disorders and cancer. Headquartered in
Dublin, Ireland, Alkermes plc has
an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in
Athlone, Ireland; and a
manufacturing facility in Wilmington,
Ohio. For more information, please visit Alkermes' website
at www.alkermes.com.
Alkermes Pathways Research Awards® is a
registered service mark of Alkermes, Inc.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Katie Joyce,
+1 781 249-8927
Video -
https://mma.prnewswire.com/media/1197039/Alkermes_Pathways_Research_Awards.mp4
Logo
- https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg